舒利迭对老年慢性阻塞性肺疾病患者的疗效观察

摘要

Objective: To observe the effect of Seretide (Fluticasone Propionate/Salmeterol) in the treatment of older patients with stable moderate chronic obstructive pulmonary disease (COPD).Methods: 120 patients were randomly divided into observation group and control group with 60 cases each group, both groups were given conventional therapy.The control group was given Theophylline Sustained-release Tablets and Ambroxol, the observation group was given inhaled Seretide.Two groups were treated for 12 weeks.Pulmonary function (FEV1/FVC, FEV1, FEV1％), 6 min walk test (6-MWD), Zung depression scores (SDS) of two groups were detected before and after treatment.Results: Compared with the control group after treatment, lung function index of the observation group [FEV1/FVC (65.98 ±15.67)％]increased significantly (P＜0.05),6-MWD [(450.9 ±19.5) m]increased significantly (P＜0.05), SDS scores [(34.50±6.81)scores]reduced (P＜0.05).Conclusion: Seretide can improve clinical symptom, lung function, physical state and mood of the patients with COPD.%目的:观察舒利迭(丙酸氟替卡松/沙美特罗)对老年稳定期慢性阻塞性肺疾病(COPD)患者的疗效.方法:将120例患者按随机分为观察组和对照组各60例,两组均按COPD稳定期常规处理,对照组给予茶碱缓释片及氨溴索,观察组给予舒利迭吸入,治疗12周,于治疗前后分别测定肺功能(FEV1/FVC,FEV1,FEV1%)、6 min步行试验、Zung抑郁量表评分(SDS).结果:与对照组治疗后相比,观察组肺功能指标[FEV1/FVC(65.98±15.67)%]明显升高(P<0.05),6 min步行实验距离[(450.9±19.5)ml明显增加(P<0.05),Zung抑郁量表评分[(34.50±6.81)分]降低(P<0.05).结论:舒利迭可减轻稳定期COPD患者的临床症状,改善肺功能,提高体力状态,改善情绪.